Screening of inhibitors of HIV-1 protease using an Escherichia coli cell assay

被引:8
作者
Buttner, J
Dornmair, K
Schramm, HJ
机构
[1] MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY
[2] MAX PLANCK INST PSYCHIAT,D-82152 MARTINSRIED,GERMANY
关键词
D O I
10.1006/bbrc.1997.6403
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To evaluate the available peptidic and pseudopeptidic inhibitors of HIV protease for their possible in vivo activity, a screening test using Escherichia coli was established. E. coli cells carrying the plasmid pET9c-PR containing the gene for HIV-1 protease under the control of a T7-promotor are grown in the absence and in the presence of inhibitors. The action of the toxic protease produced by the cells is counteracted by the inhibitors. Provided sufficient membrane permeability of the inhibitors exists, this results in accelerated cell growth. From the peptides known to be active in an in-vitro enzyme test, most compounds inhibit HIV protease only to a limited degree in this test, However, two short peptides (Ac-Ser-Tyr-Glu-Leu and Lys-Ile-Ser-Tyr-Asp-Tyr) protect cell growth to an considerabe extent, thus indicating that they reach the E. coli cytosol and there block HIV protease. Two pseudopeptides known to be very potent in the enzyme test (SDZ PRI 053 and CIBA 61755) also inhibit HIV-1 protease strongly in this cell growth test. (C) 1997 Academic Press.
引用
收藏
页码:36 / 38
页数:3
相关论文
共 16 条
[1]   ISOLATION OF MUTANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE BASED ON THE TOXICITY OF THE ENZYME IN ESCHERICHIA-COLI [J].
BAUM, EZ ;
BEBERNITZ, GA ;
GLUZMAN, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (14) :5573-5577
[2]   SDZ-PRI-053, AN ORALLY BIOAVAILABLE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEINASE-INHIBITOR CONTAINING THE 2-AMINOBENZYLSTATINE MOIETY [J].
BILLICH, A ;
FRICKER, G ;
MULLER, I ;
DONATSCH, P ;
ETTMAYER, P ;
GSTACH, H ;
LEHR, P ;
PEICHL, P ;
SCHOLZ, D ;
ROSENWIRTH, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1406-1413
[3]   PURIFICATION, ASSAY AND KINETIC FEATURES OF HIV-1 PROTEINASE [J].
BILLICH, A ;
HAMMERSCHMID, F ;
WINKLER, G .
BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1990, 371 (03) :265-272
[4]   A RAPID AND SIMPLE SCREENING METHOD FOR HIV-1 PROTEASE INHIBITORS USING RECOMBINANT ESCHERICHIA-COLI [J].
KANETO, R ;
KOJIMA, I ;
SHIBAMOTO, N ;
NISHIDA, H ;
OKAMOTO, R ;
AKAGAWA, H ;
MIZUNO, S .
JOURNAL OF ANTIBIOTICS, 1994, 47 (04) :492-495
[5]  
KLIMKAIT T, 1996, 1 EUR C EXP AIDS RES, P182
[6]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690
[7]   ANIONIC PHOSPHOLIPIDS CAN MEDIATE MEMBRANE INSERTION OF THE ANIONIC PART OF A BOUND PEPTIDE [J].
LEENHOUTS, JM ;
VANDENWIJNGAARD, PWJ ;
DEKROON, AIPM ;
DEKRUIJFF, B .
FEBS LETTERS, 1995, 370 (03) :189-192
[8]   A STRUCTURAL MODEL FOR THE RETROVIRAL PROTEASES [J].
PEARL, LH ;
TAYLOR, WR .
NATURE, 1987, 329 (6137) :351-354
[9]  
RICHARDS AD, 1990, J BIOL CHEM, V265, P7733
[10]  
ROSE JR, 1995, J VIROL, V69, P2751